News & Views
Scientists make leukaemia treatment discovery
May 17 2011
Scientists at the Wake Forest Baptist Medical Center found during the treatment of mice with leukaemia that those with a FLT3-ITD mutation, the most common type and associated with poor prognosis, that certain types of drugs frequently used in treatment protect the cancer cells.
Dr Timothy S. Pardee, an assistant professor of hematology and oncology and lead author of the study, told the journal Experimental Hematology that the FLT3-ITD mutation seems to make cells more sensitive to the impact of cytarabine, while making it almost immune to a combination of cytarabine and doxorubicin.
Scientists found that mice with the FLT3-ITD mutation succumbed to cancer at the same rate as those which were untreated.
"It's almost like the doxorubicin is protecting the cancer cells somewhat from the impact of the cytarabine, which is trying to kill the cell," Dr Pardee said.
He explained that while more research is needed, the study could prevent many leukaemia patients from having to undergo the extremely toxic doxorubicin treatment.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia